Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H de Cremoux

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Antibiotics and Chemotherapy|January 1, 1988
Prognostic value of initial chemotherapy doses in limited small cell lung cancerR Arriagada, H De Thé, F Thomas, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2008
An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patientsJ Trédaniel, C Becht, M Bekradda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1992
Extensive small-cell lung cancer. A randomized comparison of two chemotherapy programs with early crossover in instances of failure. Association pour le Traitement des Tumeurs Intra-Thoraciques (ATTIT)I Monnet, P Chariot, E Quoix, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Cisplatin and continuous infusion vindesine and 5-fluorouracil in non-small cell lung cancer (NSCLC) (ATTIT 002). ATTIT (Association pour le Traitment des Tumeurs Intra-Thoraciques)M Riggi, E Cvitkovic, H de Cremoux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancerI Monnet, P Soulié, H de Cremoux, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 1991
ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Féderation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialistsR Arriagada, T Le Chevalier, E Quoix, et al.
British Journal of Clinical Pharmacology|May 1, 1991
Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancerJ C Duche, C Joanne, J Barre, et al.
Bulletin Du Cancer|January 1, 1992
[Combination of chemotherapy (vindesine, lomustine, cisplatin, cyclophosphamide) and thoracic radiotherapy in nonresectable non-small cell bronchial carcinoma: final results of a phase II clinical trial]E Nasr, B Pellae-Cosset, R Arriagada, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques)M Riggi, P Ruffie, S Voisin, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra ThoraciquesI Monnet, S Brienza, F Hugret, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Antibiotics and Chemotherapy|January 1, 1988
Prognostic value of initial chemotherapy doses in limited small cell lung cancerR Arriagada, H De Thé, F Thomas, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2008
An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patientsJ Trédaniel, C Becht, M Bekradda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1992
Extensive small-cell lung cancer. A randomized comparison of two chemotherapy programs with early crossover in instances of failure. Association pour le Traitement des Tumeurs Intra-Thoraciques (ATTIT)I Monnet, P Chariot, E Quoix, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Cisplatin and continuous infusion vindesine and 5-fluorouracil in non-small cell lung cancer (NSCLC) (ATTIT 002). ATTIT (Association pour le Traitment des Tumeurs Intra-Thoraciques)M Riggi, E Cvitkovic, H de Cremoux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancerI Monnet, P Soulié, H de Cremoux, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 1991
ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Féderation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialistsR Arriagada, T Le Chevalier, E Quoix, et al.
British Journal of Clinical Pharmacology|May 1, 1991
Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancerJ C Duche, C Joanne, J Barre, et al.
Bulletin Du Cancer|January 1, 1992
[Combination of chemotherapy (vindesine, lomustine, cisplatin, cyclophosphamide) and thoracic radiotherapy in nonresectable non-small cell bronchial carcinoma: final results of a phase II clinical trial]E Nasr, B Pellae-Cosset, R Arriagada, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques)M Riggi, P Ruffie, S Voisin, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra ThoraciquesI Monnet, S Brienza, F Hugret, et al.
Pageof 5